Ilyang Pharmaceutical Co.,Ltd (KO:007575) — Stock Price
Ilyang Pharmaceutical Co.,Ltd (KO:007575) is currently trading at ₩7700.00 KRW, up 0.65% today. Over the past 52 weeks, shares have ranged between ₩7000.00 and ₩12980.00. This page tracks Ilyang Pharmaceutical Co.,Ltd's live share price on the KO exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see 007575 company net worth.
Ilyang Pharmaceutical Co.,Ltd (007575) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Ilyang Pharmaceutical Co.,Ltd's daily closing share price and trading volume on the KO exchange over the past year, giving a clear view of recent price momentum and liquidity.
Ilyang Pharmaceutical Co.,Ltd Income Statement — Revenue, Profit & Earnings by Year
Ilyang Pharmaceutical Co.,Ltd's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | ₩272.42 Billion | ₩268.68 Billion | ₩266.67 Billion | ₩383.81 Billion | ₩371.35 Billion |
| Cost of Revenue | ₩156.07 Billion | ₩157.39 Billion | ₩150.18 Billion | ₩167.78 Billion | ₩166.94 Billion |
| Gross Profit | ₩116.35 Billion | ₩111.29 Billion | ₩116.49 Billion | ₩216.03 Billion | ₩204.40 Billion |
| Research & Development | ₩26.10 Billion | ₩24.74 Billion | ₩23.75 Billion | ₩25.96 Billion | ₩20.20 Billion |
| SG&A | ₩28.15 Billion | ₩24.59 Billion | ₩23.95 Billion | ₩96.56 Billion | ₩89.80 Billion |
| Total Operating Expenses | ₩267.46 Billion | ₩259.06 Billion | ₩250.29 Billion | ₩343.40 Billion | ₩330.32 Billion |
| Operating Income | ₩4.96 Billion | ₩9.62 Billion | ₩16.38 Billion | ₩40.41 Billion | ₩41.03 Billion |
| EBITDA | — | — | — | ₩56.85 Billion | ₩53.64 Billion |
| EBIT | — | — | — | ₩40.41 Billion | ₩41.03 Billion |
| Interest Expense | ₩3.03 Billion | ₩2.93 Billion | ₩3.23 Billion | ₩2.46 Billion | ₩2.06 Billion |
| Income Before Tax | ₩13.26 Billion | ₩10.90 Billion | ₩-1.80 Billion | ₩41.33 Billion | ₩38.93 Billion |
| Income Tax Expense | — | — | — | ₩9.59 Billion | ₩12.97 Billion |
| Net Income | ₩6.90 Billion | ₩9.03 Billion | ₩-2.41 Billion | ₩19.24 Billion | ₩14.38 Billion |
Ilyang Pharmaceutical Co.,Ltd Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Ilyang Pharmaceutical Co.,Ltd's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | ₩457.33 Billion | ₩431.03 Billion | ₩356.66 Billion | ₩498.19 Billion | ₩494.27 Billion |
| Total Current Assets | ₩147.76 Billion | ₩125.19 Billion | ₩114.20 Billion | ₩200.73 Billion | ₩203.56 Billion |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | ₩5.97 Billion | ₩8.49 Billion | ₩6.78 Billion | ₩5.42 Billion | ₩34.34 Billion |
| Net Receivables | ₩44.97 Billion | ₩44.78 Billion | ₩46.47 Billion | ₩60.15 Billion | ₩63.16 Billion |
| Inventory | ₩64.24 Billion | ₩59.87 Billion | ₩51.78 Billion | ₩61.37 Billion | ₩41.19 Billion |
| Property, Plant & Equipment | — | — | — | ₩199.12 Billion | ₩198.31 Billion |
| Goodwill | — | — | — | — | — |
| Total Liabilities | ₩215.92 Billion | ₩191.49 Billion | ₩160.25 Billion | ₩206.33 Billion | ₩222.51 Billion |
| Total Current Liabilities | ₩171.17 Billion | ₩157.55 Billion | ₩139.19 Billion | ₩186.86 Billion | ₩198.21 Billion |
| Long-term Debt | ₩26.67 Billion | ₩14.70 Billion | ₩6.00 Billion | — | ₩5.02 Billion |
| Net Debt | ₩102.56 Billion | ₩102.91 Billion | ₩71.71 Billion | ₩25.02 Billion | ₩53.35 Billion |
| Total Stockholder Equity | ₩237.60 Billion | ₩235.95 Billion | ₩196.41 Billion | ₩234.65 Billion | ₩224.11 Billion |
| Retained Earnings | ₩122.79 Billion | ₩118.76 Billion | ₩25.55 Billion | ₩58.99 Billion | ₩43.55 Billion |
Ilyang Pharmaceutical Co.,Ltd Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Ilyang Pharmaceutical Co.,Ltd generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | ₩12.04 Billion | ₩5.61 Billion | ₩14.62 Billion | ₩29.94 Billion | ₩67.02 Billion |
| Capital Expenditures | ₩10.44 Billion | ₩40.62 Billion | ₩6.83 Billion | ₩4.08 Billion | ₩12.91 Billion |
| Free Cash Flow | ₩1.60 Billion | ₩-35.01 Billion | ₩7.79 Billion | ₩9.40 Billion | ₩45.67 Billion |
| Investing Cash Flow | — | — | — | ₩7.59 Billion | ₩-21.34 Billion |
| Financing Cash Flow | — | — | — | ₩-23.40 Billion | ₩-43.13 Billion |
| Dividends Paid | ₩2.88 Billion | ₩2.97 Billion | ₩2.99 Billion | ₩3.94 Billion | ₩8.77 Billion |
| Stock-Based Compensation | — | — | — | — | — |
| Depreciation | ₩8.34 Billion | ₩9.82 Billion | ₩11.97 Billion | ₩13.06 Billion | ₩12.65 Billion |
| Change in Cash | ₩19.36 Billion | ₩881.17 Million | ₩-3.76 Billion | ₩11.87 Billion | ₩6.39 Billion |
Ilyang Pharmaceutical Co.,Ltd Earnings History — EPS Actual vs. Analyst Estimates
Track Ilyang Pharmaceutical Co.,Ltd's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Jun 30, 2026 | -136.06 | — | — |
| Mar 31, 2026 | 996.58 | — | — |
| Dec 31, 2025 | -307.39 | — | — |
| Sep 30, 2025 | 459.30 | — | — |
| Aug 12, 2025 | 31.38 | — | — |
| Mar 31, 2025 | 190.99 | — | — |
| Mar 13, 2025 | 191.52 | — | — |
| Nov 14, 2024 | 192.15 | — | — |